Drug intelligence / Profile preview

Modified Zhiwang Decoction + methotrexate

Development stage: Unknown
Lead developer: China-Japan Friendship Hospital
Modality: Small Molecules
Administration: Oral

Overview

Modified Zhiwang Decoction (MZWD) combined with methotrexate (MTX) is a therapeutic approach that integrates traditional Chinese medicine with conventional Western medicine for the treatment of early rheumatoid arthritis (RA). MZWD is a traditional Chinese medicine formula composed of 10 herbs, developed as a modification of Bushen Quhan Zhiwang decoction (BQZD). This combination therapy aims to reduce inflammation, alleviate symptoms, and potentially slow disease progression in patients with early RA. The treatment regimen typically involves oral administration of both MZWD and MTX over a 12-week period.

Other names: MZWD + MTX

Targets

DHFR (Dihydrofolate reductase)

Beyond the preview

Go deeper on Modified Zhiwang Decoction + methotrexate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Modified Zhiwang Decoction + methotrexate.

Explore the full profile